NCI 12-C-0079 A Phase II Study of AMG 386 and abiraterone in metastatic castration resistant prostate cancer

Description:

Dual targeting of the androgen and angiogenic axis represents a novel approach as a potential targeted therapy
for patients with metastatic CRPC. AMG 386 sequesters Ang1 and Ang2, thereby preventing their interaction with Tie2 and inhibiting tumor endothelial cell (EC) proliferation and tumor growth. Abiraterone acetate is a small molecule that irreversibly inhibits CYP17, a rate-limiting enzyme in androgen biosynthesis, to block residual androgen synthesis in the adrenal gland and tumor cells. The objective of this phase II study is to estimate the treatment effect as measured by progression free survival (PFS) in patients treated with AMG 386 plus abiraterone/prednisone relative to abiraterone/prednisone alone. Eligibility requirements include prior treatment with docetaxel-based chemotherapy.

Link:

http://www.clinicaltrials.gov/ct2/show/NCT01553188?term=abiraterone+AND+prostate+AND+metastatic&rank=16

Site:

NCI

Principal Investigator:

William L. Dahut